Sustained Release Aminopyridine Composition
AssigneeAcorda Therapeutics, Inc.
InventorsAndrew R. Blight, Ron Cohen
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Claims11
1-8. (canceled)
A method of treating a disease associated with a neurological disorder, said method comprising:
- administering an aminopyridine on a dosing regimen to obtain an in vivo Cmax:Cτ ratio of 1.0 to 3.5 and a CavSS of about 15 ng/ml to about 35 ng/ml.
18-23. (canceled)
Dependencies are inferred from the claim text.